There is a history of studying relaxin in cardiovascular settings—Novartis started a phase 3 heart failure trial of a recombinant relaxin-2 peptide in 2013—but preclinical evidence of the molecule’s ...
BioCardia’s data safety monitoring board already warned that the phase 3 CardiAMP cell therapy heart failure trial was not going to make the primary endpoint. And so the California biotech is ...
Prothena Corporation plc (PRTA) just the other week announced data from its phase 3 AFFIRM-AL clinical trial using birtamimab for the treatment of patients with AL amyloidosis. The really bad news ...
Bayer’s Kerendia, already FDA approved in one cardiometabolic indication, now has data from a pivotal test that support expanding the drug’s label to heart failure. In preliminary results reported ...
CardiAMP cell therapy-treated patients had 37% relative risk reduction in heart death equivalent (death, heart transplant, left ventricular assist device implantation) and 9% relative risk reduction ...
Neuropsychiatric drug development is rife with clinical trial failures, but Alto Neuroscience aims to overcome these hurdles with a precision medicine approach that matches a patient to a drug. A ...
Cassava Sciences' Alzheimer's drug simufilam failed its Phase 3 trial, causing the stock to plummet ~90% and trade near book value. The company's decision to discontinue other simufilam trials signals ...
Shares of Cytokinetics CYTK gained 2.2% on Wednesday after the company began enrolling patients in its mid-stage study of CK-4021586 (CK-586), a cardiac myosin inhibitor, for treating heart failure ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results